Gaudium IVF IPO: Final day to bid! Apply or avoid? Market guru Anil Singhvi weighs in

Gaudium IVF IPO: The initial public offering (IPO) of Gaudium IVF and Women Health Limited stepped into the last day of its public bidding on Tuesday, February 24, 2026, with the issue subscribed over 4.54 times the public offer so far, according to the provisional exchange data. The Rs 165 crore issue is a mix of fresh issue and offer for sale (OFS).

Gaudium IVF IPO subscription status

As of 12 pm, the IPO has received bids for 6.64 crore shares against an offer of 1.46 crore shares, resulting in a 4.54 times the overall subscription so far.

Add Zee Business as a Preferred Source

The category-wise subscription details are:

• Qualified Institutional Buyers (QIBs) have booked 0.04 times, with 1.56 lakh shares bid against 41.77 lakh shares.
• Non-Institutional Investors (NIIs) have subscribed 6.93 times, with 2.17 crore shares bid against 31.32 lakh reserved.
• Retail Individual Investors (RIIs) have booked 5.29 times with 3.86 crore shares bid against 73.10 lakh shares allotted.

Gadium IVF IPO: Apply or avoid?

Earlier, Market expert Anil Singhvi, Managing Editor at Zee Business, shared his insights on Gaudium IVF and Women Health Limited's business profile and highlighted key positives and negatives.

Key positives:

Experienced and professional promoters

Scalable hub-and-spoke business model

Improved profitability due to fast turnaround of centres

Reasonable valuations

Key negatives:

Operates in a highly regulated industry

Patient inflow highly limited to promoters brand and reputation

Huge competition

What should investors do?

Market guru Anil Singhvi noted that the company operates in a unique niche with a scalable business model. He advises that risk-taking investors may consider applying, with expectations of small listing gains.

Gaudium IVF and Women Health IPO details

Gaudium IVF IPO is a book-built issue worth Rs 165 crore, consisting of a fresh issue of 1.14 crore equity shares (Rs 90 crore) and an offer for sale (OFS) of 0.95 crore shares (Rs 75 crore).

According to the company's RHP, Sarthi Capital Advisors Pvt Ltd is the book-running lead manager to the issue, while Bigshare Services Pvt Ltd has been appointed as the registrar.

Price band: The IPO is priced at Rs 75 to Rs 79 per share, giving the company a market valuation of around Rs 575 crore at the upper end.

Subscription date: The IPO opened for subscription on February 20, 2026, and will close on February 24, 2026.

Allotment date: The allotment of shares is expected to be finalised on February 25, 2026

Listing date: The IPO shares are expected to list on the stock exchanges with a tentative listing date fixed as February 27, 2026.

Lot size: Investors can apply in a lot size of 189 shares, requiring a minimum investment of Rs 14,931 for retail applicants at the upper price band.

The company has reserved 50 per cent of the net offer for Qualified Institutional Buyers (QIBs), 15 per cent for Non-Institutional Investors (NIIs), and 35 per cent for Retail Individual Investors (RIIs).

Gaudium IVF and Women Health Limited company profile

Incorporated in March 2015, Gaudium IVF and Women Health Limited provides In Vitro Fertilisation (IVF) treatments across India and has expanded into multiple states through a hub-and-spoke model.

The company operates over 30 locations, including seven hubs and 28 spokes, and has entered into a strategic alliance with Infertility Experts (Spokes) to increase awareness about Assisted Reproductive Technology (ART) and IVF treatments.

Its specialised fertility services include IVF, Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction.